These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26905040)

  • 61. Exendin-4 ameliorates diabetic symptoms through activation of glucokinase.
    Dhanesha N; Joharapurkar A; Shah G; Dhote V; Kshirsagar S; Bahekar R; Jain M
    J Diabetes; 2012 Dec; 4(4):369-77. PubMed ID: 22356440
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Combined melatonin and exendin-4 therapy preserves renal ultrastructural integrity after ischemia-reperfusion injury in the male rat.
    Yip HK; Yang CC; Chen KH; Huang TH; Chen YL; Zhen YY; Sung PH; Chiang HJ; Sheu JJ; Chang CL; Chen CH; Chang HW; Chen YT
    J Pineal Res; 2015 Nov; 59(4):434-47. PubMed ID: 26309060
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Separation of mono- and di-PEGylate of exenatide and resolution of positional isomers of mono-PEGylates by preparative ion exchange chromatography.
    Nguyen NT; Lee JS; Yun S; Lee EK
    J Chromatogr A; 2016 Jul; 1457():88-96. PubMed ID: 27363735
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Intranasal Exendin-4 modifies necroptosis-mediated innate immune response to combat septic encephalopathy in rats: Role of mTORC1 in immunogenic and tolerogenic cell demise.
    Zaky DA; Abdallah DM; El-Abhar HS
    Eur J Pharmacol; 2023 Dec; 961():176191. PubMed ID: 37967645
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification.
    Tsubery H; Mironchik M; Fridkin M; Shechter Y
    J Biol Chem; 2004 Sep; 279(37):38118-24. PubMed ID: 15190059
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intramuscular injection of palmitic acid-conjugated Exendin-4 loaded multivesicular liposomes for long-acting and improving
    Tian H; Chang M; Lyu Y; Dong N; Yu N; Yin T; Zhang Y; He H; Gou J; Tang X
    Expert Opin Drug Deliv; 2024; 21(1):169-185. PubMed ID: 38224039
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bioactivity and circulation time of PEGylated NELL-1 in mice and the potential for osteoporosis therapy.
    Zhang Y; Velasco O; Zhang X; Ting K; Soo C; Wu BM
    Biomaterials; 2014 Aug; 35(24):6614-21. PubMed ID: 24818884
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mycobacterium tuberculosis Rv2626c-derived peptide as a therapeutic agent for sepsis.
    Kim SY; Kim D; Kim S; Lee D; Mun SJ; Cho E; Son W; Jang K; Yang CS
    EMBO Mol Med; 2020 Dec; 12(12):e12497. PubMed ID: 33258196
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rational Design of Dual Agonist-Antibody Fusions as Long-acting Therapeutic Hormones.
    Liu Y; Wang Y; Zhang Y; Liu T; Jia H; Zou H; Fu Q; Zhang Y; Lu L; Chao E; Parker H; Nguyen-Tran V; Shen W; Wang D; Schultz PG; Wang F
    ACS Chem Biol; 2016 Nov; 11(11):2991-2995. PubMed ID: 27704775
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Molecular targeting of FATP4 transporter for oral delivery of therapeutic peptide.
    Hu Z; Nizzero S; Goel S; Hinkle LE; Wu X; Li C; Ferrari M; Shen H
    Sci Adv; 2020 Apr; 6(14):eaba0145. PubMed ID: 32270048
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Venoms to the rescue.
    Holford M; Daly M; King GF; Norton RS
    Science; 2018 Aug; 361(6405):842-844. PubMed ID: 30166472
    [No Abstract]   [Full Text] [Related]  

  • 72. In-medium and core-polarization effects in 50K(0(-))long-> beta -50Ca(0(+)).
    Warburton EK
    Phys Rev C Nucl Phys; 1991 Sep; 44(3):1024-1029. PubMed ID: 9967500
    [No Abstract]   [Full Text] [Related]  

  • 73. Experimental mass excess of 49K and 50K.
    Miehé C; Dessagne P; Baumann P; Huck A; Klotz G; Knipper A; Walter G; Richard-Serre C
    Phys Rev C Nucl Phys; 1986 May; 33(5):1736-1739. PubMed ID: 9953337
    [No Abstract]   [Full Text] [Related]  

  • 74. You, Me, and 50k Followers.
    Ray RG
    Obstet Gynecol; 2024 Jul; 144(1):e7. PubMed ID: 38949542
    [No Abstract]   [Full Text] [Related]  

  • 75. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.
    Holman RR; Bethel MA; George J; Sourij H; Doran Z; Keenan J; Khurmi NS; Mentz RJ; Oulhaj A; Buse JB; Chan JC; Iqbal N; Kundu S; Maggioni AP; Marso SP; Öhman P; Pencina MJ; Poulter N; Porter LE; Ramachandran A; Zinman B; Hernandez AF
    Am Heart J; 2016 Apr; 174():103-10. PubMed ID: 26995376
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.
    Cao L; Li D; Feng P; Li L; Xue GF; Li G; Hölscher C
    Neuroreport; 2016 Apr; 27(6):384-91. PubMed ID: 26918675
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Liraglutide for treating type 1 diabetes.
    Dejgaard TF; Frandsen CS; Holst JJ; Madsbad S
    Expert Opin Biol Ther; 2016; 16(4):579-90. PubMed ID: 26926662
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.
    Peng H; Want LL; Aroda VR
    Curr Diab Rep; 2016 May; 16(5):44. PubMed ID: 27037706
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany.
    Qiao Q; Grandy S; Hiller J; Kostev K
    PLoS One; 2016; 11(3):e0152281. PubMed ID: 27019360
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Proglucagon Promoter Cre-Mediated AMPK Deletion in Mice Increases Circulating GLP-1 Levels and Oral Glucose Tolerance.
    Sayers SR; Reimann F; Gribble FM; Parker H; Zac-Varghese S; Bloom SR; Foretz M; Viollet B; Rutter GA
    PLoS One; 2016; 11(3):e0149549. PubMed ID: 27010458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.